Tuesday, February 18, 2014 9:37:21 AM
GENFIT (OTC: GNFTF) today announces that the Food and Drug Administration (FDA) has granted Fast Track designation to the GFT505 development program in NASH, with effect from February 14, 2014. The FDA's Fast Track program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. The aim is to ensure that new therapies for serious conditions are approved and available to patients as soon as possible. This designation permits close and regular contact between GENFIT and the FDA, thus enabling the joint definition of the most efficient development plan through frequent meetings and an accelerated review process. GENFIT is currently conducting the Phase IIb study GFT505-212-7, for which the primary objective is to demonstrate the efficacy of one year of treatment with GFT505 (80 mg/d and 120 mg/d versus placebo) on the reversion of biopsy-diagnosed NASH. This international study involves a total of 56 centers of clinical excellence in the United States and in multiple European countries. All patients (a total of 270) have been recruited, more than half have been under treatment for more than 6 months, and the first patients have completed one year of treatment. The results should be announced at the end of 2014.
Despite it took 40% this morning in Paris ( about 40 $ / share) , the valuation of the company is still ridiculous regarding ICPT...
it seems that their molecule will be on the market before ICPT's one.. and no toxicity ...
to my opinion as a shareholder it is a big opportunity because the valuation of Genfit will raise ICPT's one in the short future
Recent ICPT News
- Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC • GlobeNewswire Inc. • 02/29/2024 01:30:00 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/20/2023 05:09:56 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/15/2023 05:15:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:49:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:49:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:47:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:46:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:46:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:45:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:44:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:44:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:43:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:43:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:42:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:42:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:40:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:40:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:40:15 PM
- Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023 • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023 • GlobeNewswire Inc. • 11/10/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:44:09 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/08/2023 09:28:58 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM